Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Bevacizumab

Pulmonary thromboembolism

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Fukuda S, et al. Relationship Between Safety and Cumulative Bevacizumab Dose in Patients With Metastatic Colorectal Cancer Who Received Long-term Bevacizumab Treatment. Anticancer Research 43: 2085-2090, No. 5, Jan 2023. Available from: URL: 10.21873/anticanres.16369 Fukuda S, et al. Relationship Between Safety and Cumulative Bevacizumab Dose in Patients With Metastatic Colorectal Cancer Who Received Long-term Bevacizumab Treatment. Anticancer Research 43: 2085-2090, No. 5, Jan 2023. Available from: URL: 10.21873/anticanres.16369
Metadaten
Titel
Bevacizumab
Pulmonary thromboembolism
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-57266-8

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Crizotinib

Case report

Nintedanib